Bispecific Antibodies: What Are They? How Do They Work? An Expert's Thoughts

May 14, 2024

In this episode of Evaluating Biopharma, host Ben Locwin speaks with Dr. Stefan Schmidt, CEO of evitria AG, about bispecific antibodies. Dr. Schmidt goes into detail about current trends (from a CRO’s perspective) regarding the discovery and development phases of bispecific antibodies, why they are being made, and potential manufacturing issues. He also discusses the future of bispecific antibodies and concerns over intellectual property immunity influencing consistency and production.

GUEST BIO

Dr. Stefan Schmidt, CEO of evitria AG
Dr. Stefan Schmidt, CEO of evitria AG in Zürich, Switzerland, is an expert in protein biochemistry, with in-depth knowledge of drug discovery up to late preclinical stage and the transition to development. Dr. Schmidt has more than two decades' experience in protein design/engineering, expression, purification, manufacture, and characterization. As COO of BioAtrium AG (a joint venture between Lonza and Sanofi), Dr. Schmidt was responsible for the start-up, implementation and leading the operations of the 20kL large scale facility, obtaining the manufacturing license, tech transfers into the GMP facility and manufacturing scale up of commercial products.

MODERATOR BIO

Ben Locwin, Vice President of Project Solutions, Black Diamond Networks
Ben Locwin is a healthcare executive and industry expert. His work has involved bringing new and innovative medical treatments (drug therapies, vaccines and medical devices) to patient populations with unmet needs across a variety of indications and health conditions. He has also worked with investors on the ‘next big things’ in the industry. He has been featured in The Wall Street Journal, Forbes, USA Today, The Associated Press, Axios, NPR, and other top-tier media.